Lung Cancer Clinical Trial
Official title:
Comparative Effectiveness of Indwelling Pleural Catheters Versus Thoracoscopic Pleurodesis for Treatment of Malignant Pleural Effusions
The goal of this clinical research study is to compare 2 different methods for treating a pleural effusion. Researchers also want to learn how the treatment you receive effects your quality of life (your ability to do the things you like to do and how happy you feel.
If you agree to take part in this study, you may be asked to fill out a questionnaire called
the MD Anderson Symptom Inventory (MDASI) before your scheduled pleural effusion treatment
procedure, 24 hours after your procedure, and then weekly for the next 4 months. During this
time, a member of the study staff or a computer system will call you at home on your desired
day and time to complete the questionnaire. The MDASI for lung-related symptoms has 22
questions about the possible symptoms caused by the disease, and how the symptoms may affect
the activities of your daily life, which you will rate on a scale of 0-10. The MDASI will
take about 5 minutes to complete each time.
You will also complete 2 questionnaires called the SF6D Patient Self Assessment and Borg
Scale before your scheduled pleural effusion treatment procedure, 2 weeks later, and then 1
time a month for 1 year. These questionnaires are part of your standard of care. There are 7
questions total about how the symptoms may affect the activities of your daily life. If you
are not in the clinic, a member of the study staff will call you at home on your desired day
and time to complete the questionnaires. The questionnaires should take about 5 minutes
total to complete each time.
Your information will be stored in a password-protected database for use in future research
related to cancer for up to 5 years after the study is completed.
Before any of your information that is stored in the database can be used for research, the
people doing the research must get specific approval from the Institutional Review Board
(IRB) of MD Anderson. The IRB is a committee made up of doctors, researchers, and members of
the community. The IRB is responsible for protecting the participants involved in research
studies and making sure all research is done in a safe and ethical manner. All research done
at MD Anderson, including research involving your data from this bank, must first be
approved by the IRB.
Your information will be given a code number so that none of your personal identifying
information will be directly linked to your information. Only the researcher in charge of
the database will have access to the code numbers and be able to link the information in the
database back to you. Other researchers who use the database will not be able to link your
information or file back to you.
This is an investigational study. Up to 445 participants will be enrolled at MD Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|